Insulin therapy

Indian Pediatrics

Volumn 43, Issue 10, 2006, Pages 863-872

  Yadav, Sangita ^a,b   Parakh, Ankit ^a  

^a LOK NAYAK HOSPITAL   (India)

^b NONE   (India)

Author keywords

Insulin analogs; Intensive insulin therapy; Noninvasive insulin delivery

Indexed keywords

GLUCOSE; INSULIN; INSULIN ASPART; INSULIN DETEMIR; INSULIN GLARGINE; INSULIN LISPRO; INSULIN ZINC SUSPENSION; ISOPHANE INSULIN; RECOMBINANT HUMAN INSULIN;

AGE DISTRIBUTION; CLINICAL TRIAL; COST BENEFIT ANALYSIS; DIABETIC DIET; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG COST; DRUG DELIVERY SYSTEM; DRUG DOSE REGIMEN; DRUG SUBSTITUTION; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HUMAN; HYPOGLYCEMIA; INSULIN DEPENDENT DIABETES MELLITUS; LIPID VESICLE; META ANALYSIS; NOSE IRRITATION; REVIEW; RISK ASSESSMENT; SYSTEMATIC REVIEW; UNSPECIFIED SIDE EFFECT;

ADOLESCENT; ADULT; CHILD; CHILD, PRESCHOOL; DIABETES MELLITUS, TYPE 1; HUMANS; INFANT; INFANT, NEWBORN; INSULIN;

EID: 33750363709     PISSN: 00196061     EISSN: 00196061     Source Type: Journal    
DOI: None     Document Type: Review

References (37)

1. The Diabetes Control and Complications Trial Research Group. The effect of intensive therapy of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993; 329: 977-986.
2. ADA Statement: Care of Children and Adolescents With Type 1 Diabetes. Diabetes Care 2005; 28:186-212.
3. DAFNE Study Group: Training in flexible, intensive insulin management to enable dietary freedom in people with type 1 diabetes: Dose adjustment for normal eating (DAFNE) randomized controlled trial. BMJ 2002; 325: 746-752.
4. Siebenhofer A, Plank J, Berghold A, Narath M, Gfrerer R, Pieber TR. Short acting insulin analogues versus regular human insulin in patients with diabetes mellitus. Cochrane Database Syst Rev 2004;(2): CDO03287.
5. Plank J, Siebenhofer A, Berghold A, Jeitler K, Horvath K, Mrak P, et al. Systematic review and meta-analysis of short-acting insulin analogues in patients with diabetes mellitus. Arch Intern Med 2005; 165: 1337-1344.
6. Reynolds NA, Wagstaff RD. Insulin aspart: A review. Drugs. 2004; 64: 1957-1974.
7. Siebenhofer A, Plank J, Berghold A, Horvath K, Sawicki PT, Beck P, et al. Meta-analysis of short-acting insulin analogues in adult patients with type 1 diabetes: continuous subcutaneous insulin infusion versus injection therapy. Diabetologia 2004; 47: 1895-1905.
8. Davey P, Grainger D, MacMillan J, Rajan N, Aristides M, Gliksman M. Clinical outcomes with insulin lispro compared with human regular insulin: a meta-analysis. Clin Ther 1997; 19: 656-674.
9. Rutledge KS, Chase HP, Klingensmith GJ, Walravens PA, Slover RH, Garg SK. Effectiveness of postprandial humalog in toddlers with diabetes. Pediatrics 1997; 100: 968-972.
10. Roach P, Trautmann M, Arora V, Sun B, Anderson JH Jr. Improved postprandial blood glucose control and reduced nocturnal hypoglycemia during treatment with two novel insulin lispro-protamine formulations, insulin lispro mix 25 and insulin lispro mix 50. Mix 50 Study Group. Clin Ther 1999; 21: 523-534.
11. Roach P, Strack T, Arora V, Zhao Z. Improved glycaemic control with the use of self-prepared mixtures of insulin lispro and insulin lispro protamine suspension in patients with types 1 and 2 diabetes. Int J Clin Pract 2001; 55: 177-182.
12. Raskin P, Klaff L, Bergenstal R, Halle JP, Donley D, Mecca T. A 16-week comparison of the novel insulin analog insulin glargine (HOE 901) and NPH human insulin used with insulin lispro in patients with type 1 diabetes. Diabetes Care 2000; 23: 1666-1671.
13. Ratner RE, Hirsch IB, Neifing JL, Garg SK, Mecca TE, Wilson CA. Less hypoglycemia with insulin glargine in intensive insulin therapy for type 1 diabetes. U.S. Study Group of Insulin Glargine in Type 1 Diabetes. Diabetes Care 2000; 23: 639-643.
14. Rossetti P, Pampanelli S, Fanelli C, Porcellati F, Costa E, Torlone E, Scionti L, Bolli G B. Intensive replacement of basal insulin in patients with type 1 diabetes given rapid-acting insulin analog at mealtime. Diabetes Care 2003; 26: 1490-1496.
15. Rosenstock J, Park G, Zimmerman J. Basal insulin glargine (HOE 901) versus NPH insulin in patients with type 1 diabetes on multiple daily insulin regimens. U.S. Insulin Glargine (HOE 901) Type 1 Diabetes Investigator Group. Diabetes Care 2000; 23: 1137-1142.
16. Rosenstock J, Dailey G, Benedetti M M, Fritsche A, Un Z, Alan S. Reduced hypoglycemia risk with insulin glargine. Diabetes Care 2005; 28: 950-955.
17. Kudva YC, Basu A, Jenkins GD, Pons GM, Quandt LL, Gebel JA, et al. Randomized controlled clinical trial of glargine versus ultralente insulin in the treatment of type 1 diabetes. Diabetes Care 2005; 28: 10-14.
18. Murphy NP, Keane SM, Ong KK, Adams MF, Edge JA, Acerini CL, et al. Randomized crossover trial of insulin glargine plus lispro or nph insulin plus regular human insulin in adolescents with type 1 diabetes on intensive insulin regimens. Diabetes Care 2003; 26: 799-804.
19. Khadilkar VV, Khadilkar AV. Concomitant use of insulin glargine and NPH in type I diabetes. Indian Pediatr 2005; 42: 796-800.
20. Pieber TR, Draeger E, Kristensen A, Grill V. Comparison of three multiple injection regimens for type 1 diabetes: morning plus dinner or bedtime administration of insulin detemir vs. morning plus bedtime NPH insulin. Diabet Med 2005; 22: 850-857.
21. Hermansen K, Madsbad S, Perrild HI Kristensen A, Axelsen M. Comparison of the soluble basal insulin analog detemir with NPH insulin: a randomized open crossover trial in type 1 diabetic subjects. Diabetes Care 2001; 24: 296-301.
22. Vague PI Selam JL, Skeie S, De Leeuw I, Elte JWF, Haahr H, et al. Insulin detemir is associated with more predictable glycemic control and reduced risk of hypoglycemia than NPH insulin in patients with type 1 diabetes on a basal-bolus regimen with premeal insulin aspart. Diabetes Care 2003; 26: 590-596.
23. Standi EI, Lang H, Roberts A. The 12-month efficacy and safety of insulin detemir and NPH insulin in basal-bolus therapy for the treatment of type 1 diabetes. Diabetes Technol Ther 2004; 6: 579-588.
24. Insulin Administration: Position Statement. American Diabetes Association. Diabetes Care 2001; 24: 1984-1987.
25. Pickup J, Mattock M, Kerry S. Glycaemic control with continuous subcutaneous insulin infusion compared with intensive insulin injections in patients with type 1 diabetes: Meta-analysis of randomized controlled trials. BMJ 2002; 324: 705-709.
26. Pickup J, Keen H. Continuous subcutaneous insulin infusion at 25 years: evidence base for the expanding use of insulin pump therapy in type 1 diabetes. Diabetes Care 2002; 25: 593-598.
27. Dunbar JM, Madden PM, Gleeson DT, Fiad TM, McKenna TJ. Premixed insulin preparations in pen syringes maintain glycemic control and are preferred by patients. Diabetes Care 1994; 17: 874-878.
28. Korytkowski M, Bell O, Jacobsen C, Suwannasari R. FlexPen Study Team. A multicenter, randomized, open-label, comparative, two-period crossover trial of preference, efficacy, and safety profiles of a prefilled, disposable pen and conventional vial/syringe for insulin injection in patients with type 1 or 2 diabetes mellitus. Clin Ther 2003; 25: 2836-2848.
29. Coscelli C, Calabrese G, Fedele D, Pisu E, Calderini C, Bistoni S, et al. A use of premixed insulin among the elderly. Reduction of errors in patient preparation of mixtures. Diabetes Care 1992; 15: 1628-1630.
30. Cevc G, Gebauer D, Stieber J, Schatzlein A, Blume G. Ultraflexible vesicles, transfersomes, have an extremely low pore penetration resistance and transport therapeutic amounts of insulin across the intact mammalian skin. Biochem Biophys Acta 1998; 1368: 201-215.
31. Hilsted J, Madsbad S, Hvidberg A, Rasmussen MH, Krarup T, Ipsen H, et al. Intranasal insulin therapy: the clinical realities. Diabetologia 1995; 38: 680-684.
32. Jacobs MA, Schreuder RH, Jap-A-Joe K, Nauta JJ, Andersen PM, Heine RJ. The pharmacodynamics and activity of intranasal administered insulin in healthy male volunteers. Diabetes 1993; 42: 1649-1655.
33. Gordon GS, Moses AC, Silver RD, Flier JS, Carey MC. Nasal absorption of insulin: enhancement by hydrophobic bile salts. Proc Natl Acad Sci US A 1985; 82: 7419-7423.
34. Heinemann l. Alternative delivery routes: Inhaled insulin. Diabetes Nutr Metab 2002; 15: 417-422.
35. Laube Bl, Georgopoulus A, Adams GK III. Preliminary study of the efficacy of insulin aerosol delivered by oral inhalation in diabetic subjects. JAMA 1993; 269: 2106-2109.
36. Royle P, Waugh N, McAuley L, Mcintyre L, Thomas S. Inhaled insulin in diabetes mellitus. Cochrane Database Syst Rev 2004;(3): CD003890.
37. Clement S, Dandona P, Still G, Kosutic G. Oral modified insulin (HIM2) in patients with type 1 diabetes mellitus: results from a phase I/II clinical trial. Metabolism 2004; 53: 54-58.